<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of tuberculosis infection (latent tuberculosis) in pregnancy*&lt;sup&gt;¶&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of tuberculosis infection (latent tuberculosis) in pregnancy*<sup>¶</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of tuberculosis infection (latent tuberculosis) in pregnancy*<sup>¶</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="30%"></colgroup><colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1">Regimen</td> <td class="subtitle1">Dosing</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Rifamycin-based regimens<sup>Δ</sup></td> </tr> <tr> <td class="indent1">Rifampin (daily for 4 months; 4R)</td> <td> <ul> <li>Rifampin 10 mg/kg (600 mg maximum) orally daily for 4 months</li> </ul> </td> </tr> <tr> <td class="indent1">Isoniazid<sup>◊</sup> <strong>plus</strong> rifampin (daily for 3 months; 3HR)</td> <td> <ul> <li>Isoniazid 5 mg/kg (300 mg maximum) orally daily for 3 months <ul class="none"> <li><strong>plus</strong></li> </ul> </li> <li>Rifampin 10 mg/kg (600 mg maximum) orally daily for 3 months</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Isoniazid monotherapy regimens</td> </tr> <tr> <td class="indent1">Isoniazid<sup>◊</sup> (daily for 9 or 6 months; 9H or 6H)</td> <td> <ul> <li>Isoniazid 5 mg/kg (300 mg maximum) orally daily for 9 or 6 months<sup>§</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">The efficacy and toxicity of these regimens differ, and some are appropriate only for certain patient populations. For a discussion of the clinical approach to the timing and regimen selection for treatment of tuberculosis infection, refer to the UpToDate topic on treatment of tuberculosis infection in pregnancy. Dosing assumes normal renal and hepatic function. For nonobese individuals, dosing for isoniazid and rifampin is based on actual body weight; optimal dosing for obese individuals has not been established.</div><div class="graphic_footnotes"><p>TST: tuberculin skin test;
    IGRA: interferon-gamma release assay;
    TBI: tuberculosis infection.</p>
<p>* The regimens summarized in the table are for treatment of TBI due to <em>Mycobacterium tuberculosis</em> presumed to be susceptible to isoniazid and rifamycins. For details regarding treatment of drug-resistant TBI, refer to the UpToDate topic on treatment of TBI.</p>
<p>¶ Tuberculosis terminology is inconsistent in the literature. Tuberculosis infection is a newer term for latent tuberculosis infection (older term); these terms refer to the clinical state in which there is evidence of cell-mediated immunologic response following exposure to <em>Mycobacterium tuberculosis</em>-derived protein antigens in solution (eg, positive TST and/or IGRA), in the absence of signs or symptoms of illness. Terms referring to presence of signs or symptoms reflecting illness due to <em>M. tuberculosis</em> include tuberculosis disease (newer term) or active tuberculosis (older term).</p>
<p>Δ Safety data for rifapentine in pregnancy are limited; therefore, neither the three-month weekly isoniazid and rifapentine (3HP) regimen nor the one-month daily isoniazid and rifapentine (1HP) regimen are recommended for individuals who are pregnant or expecting to become pregnant during the treatment period.</p>
<p>◊ Peripheral neuropathy can occur among patients on TBI regimens containing isoniazid due to interference with metabolism of pyridoxine and can be prevented with pyridoxine (vitamin B6) supplementation (25 to 50 mg daily). This is especially important for patients with pregnancy as well as seizure disorders and conditions that can predispose to neuropathy (including diabetes, uremia, alcoholism, malnutrition, and HIV infection). Breastfed infants whose mothers are taking isoniazid do not require pyridoxine supplementation (unless the infant is also receiving isoniazid themselves).</p>
    § If isoniazid is used, we favor daily administration for 9 months (9H) given its established efficacy. Isoniazid daily for 6 months (6H) provides some protection; in the setting of difficulty with adherence, providers may prefer to concentrate efforts in ensuring 6 months of therapy. This approach is favored by the World Health Organization. However, regimens shorter than 9 months should not be used for patients with fibrotic lesions on chest radiograph.</div><div class="graphic_reference">References:
<ol>
<li>World Health Organization. WHO consolidated guidelines
    on tuberculosis: Module 1: Prevention: Tuberculosis preventive treatment. <a href="https://apps.who.int/iris/handle/10665/331170" target="_blank">https://apps.who.int/iris/handle/10665/331170</a> (Accessed on August 15, 2022).</li>
<li>Sterling T, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations From the National Tuberculosis Controllers Association and CDC, 2020. MMWR 2020; 69:1.</li>
<li>United States Centers for Disease Control and Prevention. Treatment for TB Disease &amp; Pregnancy. <a href="https://www.cdc.gov/tb/topic/treatment/pregnancy.htm" target="_blank">https://www.cdc.gov/tb/topic/treatment/pregnancy.htm</a> (Accessed on August 15, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 73637 Version 15.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
